title: An open multicentre study of the treatment of florid schizophrenia with remoxipride.
abstract: Remoxipride, a novel substituted benzamide, was given for 4 weeks to 18 florid schizophrenics in an open study. The mental state of the majority improved as measured by the Brief Psychiatric Rating Scale. Remoxipride itself did not appear to cause troublesome extrapyramidal effects. There were no significant adverse effects on the cardiovascular system and no significant abnormalities in laboratory tests. These results suggest that remoxipride has antipsychotic effects, and that this should be tested in controlled clinical trials.
authors.forename: R G
authors.initials: RG
authors.lastname: McCreadie
authors.forename: D
authors.initials: D
authors.lastname: Morrison
authors.forename: D
authors.initials: D
authors.lastname: Eccleston
authors.forename: R G
authors.initials: RG
authors.lastname: Gall
authors.forename: J
authors.initials: J
authors.lastname: Loudon
authors.forename: M J
authors.initials: MJ
authors.lastname: Mitchell
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011954:Receptors, Dopamine / Q000187:drug effects; D017448:Receptors, Dopamine D2; D017330:Remoxipride; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D001549:Benzamides; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D017330:Remoxipride